Zai Lab Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (14)

Latest Posts

About This Stock More About This Stock
Week In Review: Bio-Thera Raises $241 Million In Shanghai STAR IPO For Antibody Portfolio
Article By: ChinaBio® Today
Saturday, February 15, 2020 4:19 PM EST
Bio-Thera Solutions of Guangzhou priced its IPO on Shanghai’s STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed.
In this article: JNJ, ROG, GILD, ZLAB
Read
Week In Review: AkesoBio Files For $300 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, February 8, 2020 4:16 PM EST
AkesoBio, a Zhongshan novel drug discovery and development biopharma, filed for a $300 million Hong Kong IPO to develop its portfolio of novel mono- and bi-specific antibodies.
In this article: ZLAB, GILD
Read
Week In Review: South Korea's Celltrion Plans $513 Million Biologics Facility In Wuhan
Article By: ChinaBio® Today
Saturday, January 25, 2020 4:50 PM EST
Celltrion, a South Korea biopharma, plans to build a $513 million China biologics manufacturing facility in Wuhan. The company said the plant's 120,000 liter capacity will make it the largest facility in China.
In this article: ROG, ZLAB
Read
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
Article By: ChinaBio® Today
Saturday, January 11, 2020 4:11 PM EST
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.
In this article: LLY, GLYC, BPMC, ZLAB
Read
Week In Review: 2018 Results: China Life Science Investment Hits Record Levels
Article By: ChinaBio® Today
Saturday, January 5, 2019 4:28 PM EST
Investments in China life science set new records in all categories during 2018, reflecting the increasing development of the industry. And these numbers are spectacular even in comparison to an already strong 2017.
In this article: NVCR, ATNX, ZLAB
Read

PARTNER HEADLINES

Latest Tweets for $ZLAB

No tweets yet!